<DOC>
	<DOCNO>NCT00775086</DOCNO>
	<brief_summary>The purpose single center , randomize , double-blind , 2 way crossover study determine bioequivalence norelgestromin/ethinyl estradiol ( NGMN/EE ) transdermal contraceptive system .</brief_summary>
	<brief_title>Bioequivalence Study Patches With Different Equilibration Profiles</brief_title>
	<detailed_description>The primary objective determine bioequivalence norelgestromin/ethinyl estradiol ( NGMN/EE ) transdermal contraceptive system lot fast equilibration profile compare currently market lot NORELGESTROMIN/ETHINYL ESTRADIOL , application buttock . This single center , randomize , double-blind , 2 way crossover study . The double-blind treatment phase include two 7-day treatment period separate 21-day washout period . Safety assess throughout study . The study population comprise healthy woman weigh least 110 pound body mass index ( BMI ) 16 29.9 kg/m2 , hematocrit least 36 % . Eligible patient randomly assign 1 2 treatment sequence group . A 20 cm2 NGMN/EE transdermal contraceptive patch ( test NORELGESTROMIN/ETHINYL ESTRADIOL ( reference ) apply patient buttock wear 7 day . Twenty-one day removal first patch patient cross treatment . After patch remove , skin check redness swell . Blood sample collect measurement drug concentration 7-day wear period 3 day patch remove . Patients telephone weekly washout period remind use back-up contraception . After last blood sample collection Period 2 , instance patient withdraw early study , posttreatment procedure include physical gynecologic examination , vital sign , laboratory evaluation , serum pregnancy test perform . The following pharmacokinetic parameter estimate NGMN , NG , EE test NORELGESTROMIN/ETHINYL ESTRADIOL patch application : Cmax - maximum observe serum concentration patch application ; tmax - time maximum serum concentration patch application ; Css - mean steady-state concentration NGMN EE patch application calculate mean concentration 48 168 hour ; Cavg - average concentration NG calculate AUC168/168 ; AUC - area serum concentration-time curve NGMN , NG , EE use linear trapezoidal summation data obtain patch application time 0 ( dose ) 168 hour postdose ( AUC168 ) , time 0 240 hour postdose ( AUC240 ) , time 0 infinity ( AUCinf ) , time 0 last measurable concentration EE ( AUClast ) ; tÂ½ - apparent terminal half-life , compute ( ln2/ke ) ke slope terminal log-linear phase serum concentration-time curve . Patch adhesion assessed score summarize . Assessment bioequivalence base use 90 % confidence interval ( 2 one-sided test procedure ) ratio mean ( test reference ) pharmacokinetic parameter , AUC240 Css NGMN EE . The 2 patch consider bioequivalent 90 % confidence interval fell within 80 % 125 % limit AUC240 Css NGMN EE . Safety evaluation base adverse event , include erythema application site reaction change physical gynecologic examination ( include breast exam ) , vital sign , 12-lead ECGs , clinical laboratory test result pre- poststudy . Serum pregnancy test urine drug screening perform . Changes screen summarize use descriptive statistic . A fast equilibratin patch NORELGESTROMIN/ETHINYL ESTRADIOL patch ( 20 cm2 transdermal contraceptive system ) contain NGMN 6.0 mg EE 0.75 mg. Each patient wear patch ( test NORELGESTROMIN/ETHINYL ESTRADIOL ) buttock 7 day , accord computer-generated randomization schedule . There 21-day washout period . Patients cross treatment 7 day .</detailed_description>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy determine physical gynecologic examination , clinical laboratory assessment , vital sign measurement , 12lead electrocardiogram ( ECG ) Pregnant Lactating Currently use hormonal contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>ORTHO EVRA</keyword>
	<keyword>contraception</keyword>
	<keyword>NGMN</keyword>
	<keyword>contraceptive patch</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>EE</keyword>
	<keyword>norelgestromin</keyword>
	<keyword>ethinyl estradiol</keyword>
</DOC>